Browse studies

Find your next paid study

1,241 recruiting studies matching your filters

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each particip…

Chronic Obstructive Pulmonary Disease (COPD)Allergies

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07059091

Phase 2

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-aller…

Drug AllergyCephalosporin AllergyDrug Hypersensitivity+4 more

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06406114

Phase 2

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two subst…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

BioNTech SENCT06712316

Phase 2

A Randomized Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells (VSTs) for Control of Viral Infections After Allogeneic Stem Cell Transplant

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent or treat viral infections that may happen a…

Allogeneic Stell Cell TransplantViral Infection

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT04230356

Phase 1

Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors

This phase I trial tests the safety, side effects, and best dose of azenosertib in combination with trastuzumab deruxtecan in treating patients with HER2-posit…

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more

Estimated

~$10 – $5,625

Phase 1

A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug d…

Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more

Estimated

~$10 – $8,750

Cogent Biosciences, Inc.NCT07361562

Phase 1

Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

Rates of bacterial sexually transmitted infections (STIs) are rising globally, demanding innovative interventions beyond the scope of current efforts to preven…

Sexually Transmitted Diseases, Bacterial

Estimated

~$10 – $5,625

University of California, San FranciscoNCT06414408

Phase 1

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to ope…

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT04802759

Phase 1

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung …

ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer

Estimated

~$10 – $8,750

TRIANA Biomedicines, Inc.NCT07491497

An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform aph…

Solid Tumor, AdultColorectal CancerNon Small Cell Lung Cancer+14 more

Estimated

~$10 – $1,050

A2 Biotherapeutics Inc.NCT04981119

Phase 3

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced hea…

Locally Advanced Head and Neck Squamous Cell Carcinoma

Estimated

~$10 – $7,500

AstraZenecaNCT06129864

Phase 3

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (O…

Non-small Cell Lung Cancer (NSCLC)

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06170788